Susceptibility of highly pathogenic A(H5N1) avian influenza viruses to the neuraminidase inhibitors and adamantanes

Bresson, 2006, Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial, Lancet, 367, 1657, 10.1016/S0140-6736(06)68656-X

Bright, 2006, Adamantane resistance among influenza A viruses isolated early during the 2005–2006 influenza season in the United States, JAMA, 295, 891, 10.1001/jama.295.8.joc60020

Cheung, 2006, Distribution of amantadine-resistant H5N1 avian influenza variants in Asia, J. Infect. Dis., 193, 1626, 10.1086/504723

Gubareva, 2004, Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors, Virus Res., 103, 199, 10.1016/j.virusres.2004.02.034

Hay, 1985, The molecular basis of the specific anti-influenza action of amantadine, EMBO J., 4, 3021, 10.1002/j.1460-2075.1985.tb04038.x

Hayden, 2006, Antivirals for influenza: historical perspectives and lessons learned, Antiviral Res., 71, 372, 10.1016/j.antiviral.2006.05.016

Hurt, 2004, Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir, Antiviral Res., 62, 37, 10.1016/j.antiviral.2003.11.008

Hurt, 2006, Neuraminidase inhibitor-resistant and -sensitive influenza B viruses isolated from an untreated human patient, Antimicrob. Agents Chemother., 50, 1872, 10.1128/AAC.50.5.1872-1874.2006

Kiso, 2004, Resistant influenza A viruses in children treated with oseltamivir: descriptive study, Lancet, 364, 759, 10.1016/S0140-6736(04)16934-1

Lokuge, 2006, Pandemics, antiviral stockpiles and biosecurity in Australia: what about the generic option?, Med. J. Aust., 184, 16, 10.5694/j.1326-5377.2006.tb00089.x

Munster, 2005, Mallards and highly pathogenic avian influenza ancestral viruses, northern Europe, Emerg. Infect. Dis., 11, 1545, 10.3201/eid1110.050546

Peng, 2000, Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation, Antimicrob. Agents Chemother., 44, 1974, 10.1128/AAC.44.7.1974-1976.2000

Roche, 2006. Tamiflu (Oseltamivir carboxylate) Capsules and for Oral Suspension. (www.tamiflu.com), Package Insert.

Russell, 2006, The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design, Nature, 443, 45, 10.1038/nature05114

Stephenson, 2006, Development and evaluation of influenza pandemic vaccines, Lancet Infect. Dis., 6, 71, 10.1016/S1473-3099(06)70364-4

Tam, 2005, Fortune favours the prepared mind: a national perspective on pandemic preparedness, Can. J. Public Health, 96, 406, 10.1007/BF03405177

WHO, 2006. Avian Influenza, http://www.who.int/csr/disease/avian_influenza/en/index.html

Wood, 2001, Developing vaccines against pandemic influenza, Philos. Trans. R. Soc. Lond. B Biol. Sci., 356, 1953, 10.1098/rstb.2001.0981